MedTrace Logo

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

NCT00003405 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-10-14

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining more than one chemotherapy drug with biological therapy may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, isotretinoin, and interferon alfa in treating patients who have acute myelogenous leukemia.

Conditions

Interventions

BIOLOGICAL

recombinant interferon alfa

DRUG

amifostine trihydrate

DRUG

bromodeoxyuridine

DRUG

cytarabine

DRUG

idarubicin

DRUG

idoxuridine

DRUG

isotretinoin

DRUG

mitoxantrone hydrochloride

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Philip D. Bonomi, MD · Rush University Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
0 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
1999-04-30
Completion
1999-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003405 on ClinicalTrials.gov